Pipeline

Pipeline of Vaccines and Antibodies

R&D Preclinical Phase 1 Phase 2 Phase 3
PNV

(Multivalent Antibacterial Vaccine)

UNImAb

(Multivalent Antibacterial Monoclonal Antibodies)

SILBA

(SARS-CoV-2 Vaccine)

Status
PNV

(Multivalent Antibacterial Vaccine)

Preclinical
UNImAb

(Multivalent Antibacterial Monoclonal Antibodies)

R&D
SILBA

(SARS-CoV-2 Vaccine)

Preclinical

* PNV is a vaccine addressing the following bacteria:

  • Escherichia coli + Klebsiella pneumoniae
  • Staphylococcus aureus (incl. MRSA and VRSA)
  • Streptococcus pneumoniae
  • Group B Streptococcus

**UNImAb are monoclonal antibodies addressing the following bacteria:

  • Escherichia coli + Klebsiella pneumoniae
  • Staphylococcus aureus (incl. MRSA and VRSA)
  • Streptococcus pneumoniae
  • Group B Streptococcus

*** SILBA is a vaccine addressing the SARS-CoV-2 virus

PNV

Paragon Novel Vaccine (PNV) is a breakthrough vaccine providing effective protection against bacterial infections caused by 5 different bacteria: S. aureus, S. pneumoniae, K. pneumoniae, E. coli and S. agalactiae (GBS). 

PNV works by blocking an extracellular form of bacterial GAPDH, while not reacting with human GAPDH. As such, the host immune system will react against the infection by eliminating the bacteria. 

Preclinical trials on animal models have demonstrated high levels of efficacy against all 5 bacteria with a strong safety profile. 

PNV will become the world’s first vaccine preventing multiple bacterial infections for all its invasive serotypes, including multi-resistant strains.

The vaccine is a peptide based immunotherapy which is stable at high temperatures and it is not freeze sensitive

UNImAb

Immunethep is developing a therapeutic immunotherapy based on monoclonal antibodies with the following characteristics:

  • Monoclonal antibody (IgG1) targeting bacterial GAPDH;
  • Treats infection from all invasive serotype of multiple bacteria;
  • Very low probability of inducing resistance;
  • Microbiome friendly

SILBA

Immunethep has focused on developing a vaccine capable of optimising lung-specific immunity against the different variants of the virus. This proof-of-concept takes advantage of the high homology between the SARS-CoV-2 strain and the rest of the SARS-CoV family. By using the inactivated whole virus as the target antigen, the vaccine maximises the number of B- and T-cell epitopes and thus the immunogenicity of the vaccine.

Additionally, by maximizing the number of viral epitopes present in the vaccine, it decreases the probability of point mutations that escape vaccine efficacy, thus ensuring protection against different variants. This is not the case with the currently available EU approved vaccines that target the Spike protein, whether using recombinant technology, adenovirus, or even DNA/RNA. 

The vaccine developed by Immunethep is inhalable, promoting robust antiviral responses against this virus in the nasopharynx and in the lung, the route of entry into the body. This confers to SILBA the ideal characteristics not only to provide initial immunity to unvaccinated population, but also to be used as an immunity booster to vaccines already administered, as it has a high and unchanged response capacity to new variants of the virus.